Dr. Hayslip to lead development programs for avutometinib, including Verastem Oncology’s international confirmatory Phase 3 RAMP 301 clinical trial, and advance pipeline assets BOSTON, April 18, 2024...
Source LinkDr. Hayslip to lead development programs for avutometinib, including Verastem Oncology’s international confirmatory Phase 3 RAMP 301 clinical trial, and advance pipeline assets BOSTON, April 18, 2024...
Source Link
Comments